ストックスクリーナーアプリを入手
1.715
1.18%
0.025
前日終値:
$1.69
開ける：
$1.71
24時間の取引高:
20,230
Relative Volume:
0.02
時価総額：
$350.89M
収益：
$893.00K
当期純損益:
$-151.61M
株価収益率:
-3.3288
EPS:
-0.5152
ネットキャッシュフロー:
$-135.31M
1週間 パフォーマンス:
+1.18%
1か月 パフォーマンス:
-8.06%
6か月 パフォーマンス:
-19.34%
1年 パフォーマンス:
+134.25%
1日の値動き範囲:
$1.68
$1.711
1週間の範囲:
$1.59
$1.806
52週間の値動き範囲:
$0.54
$7.13
Prokidney Corp Stock (PROK) Company Profile
Compare PROK vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
1.71 | 346.79M | 893.00K | -151.61M | -135.31M | -0.5152 |
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.08 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.85 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.68 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.56 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-16 | 開始されました | H.C. Wainwright | Buy |
| 2025-06-30 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-09-30 | 開始されました | JP Morgan | Neutral |
| 2024-09-10 | 開始されました | Guggenheim | Buy |
| 2024-03-07 | 再開されました | Morgan Stanley | Equal-Weight |
| 2024-01-02 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-07-25 | 開始されました | BTIG Research | Buy |
| 2022-12-21 | 開始されました | Jefferies | Buy |
| 2022-11-10 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-10-18 | 開始されました | UBS | Buy |
| 2022-10-14 | 開始されました | Citigroup | Buy |
| 2022-09-23 | 開始されました | BofA Securities | Buy |
| 2022-09-02 | 開始されました | Evercore ISI | Outperform |
すべてを表示
Prokidney Corp (PROK) 最新ニュース
Number of shareholders of ProKidney Corp. – NASDAQ:PROK - TradingView
PROK Technical Analysis | Trend, Signals & Chart Patterns | PROKIDNEY CORP (NASDAQ:PROK) - ChartMill
PROK Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus
Analyst Maintains Sell on ProKidney Amid Single-Asset Risk and Long Path to 2028 BLA, Keeps $1 Price Target Below Market - TipRanks
ProKidney's first-quarter loss grows with increased operating expenses - Winston-Salem Journal
ProKidney Corp. (PROK) reports Q1 loss, tops revenue estimates - MSN
ProKidney Releases Q1 2026 Financial Results - AlphaStreet
Prokidney Corp reports results for the quarter ended March 31Earnings Summary - TradingView
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
ProKidney reports Q1 EPS (14c), consensus (14c) - TipRanks
ProKidney Highlights Progress in Pivotal Phase 3 CKD Trial - TipRanks
ProKidney Q1 loss widens as R&D spending rises - TradingView
PROKIDNEY CORP. 1Q 2026: Revenue $0.226M, EPS $(0.14) — 10-Q Summary - TradingView
PROK: Phase 3 trial enrollment on track; cash runway extends into mid-2027 amid rising R&D costs - TradingView
ProKidney Corp. Reports Phase 3 PROACT 1 Study Enrollment Progress and Q1 2026 Financial Results - Quiver Quantitative
PROK: Net loss widened to $42.6M in Q1 2026 as R&D spending rose for Phase 3 trials - TradingView
[8-K] PROKIDNEY CORP. Reports Material Event - Stock Titan
ProKidney (NASDAQ: PROK) Q1 2026 loss, R&D spend and cash runway to 2027 - Stock Titan
Kidney disease cell therapy ProKidney eyes key 2027 trial results - Stock Titan
BRIEF-ProKidney Q1 Operating Income USD -44.933 Million - TradingView
Press Release: ProKidney Reports First Quarter 2026 Financial Results and Business Highlights - Moomoo
TradingKey - TradingKey
PROKIDNEY CP (PROK) Eps Diluted (TTM) - Zacks Investment Research
ProKidney Corp. (NASDAQ:PROK) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
3 Promising Penny Stocks With Market Caps Up To $600M - Sahm
ProKidney (PROK) to Release Quarterly Earnings on Monday - MarketBeat
ProKidney approaches pivotal research, funding crossroads for drug therapy - Winston-Salem Journal
ProKidney Names Greg Madison as Chief Commercial Officer - HarianBasis.co
PROK - Finviz
ProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for Rilparencel - Insider Monkey
[SCHEDULE 13D/A] PROKIDNEY CORP. Amended Major Shareholder Report - Stock Titan
Control Empresarial converts 63.1M PROK (NASDAQ: PROK) Paired Interests into Class A shares - Stock Titan
Culleton - Winston-Salem Journal
9 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey
MSN Money - MSN
ProKidney spikes after mid-stage trial data for lead asset - MSN
ProKidney's top executive gains nearly threefold hike in 2025 compensation - Winston-Salem Journal
ProKidney (PROK) Stock Live Trade (On the Radar) 2026-04-20Late Breakout - Cổng thông tin điện tử tỉnh Lào Cai
ProKidney (NASDAQ:PROK) Upgraded to Sell at Wall Street Zen - MarketBeat
ProKidney (NASDAQ:PROK) Stock Price Up 9%Should You Buy? - MarketBeat
Executive pay, governance on agenda at ProKidney (NASDAQ: PROK) vote - Stock Titan
ProKidney Corp. (NASDAQ:PROK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
ProKidney (PROK) Stock: Trend Strength (Buying Pressure) 2026-04-15AI Powered Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
ProKidney (NASDAQ:PROK) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Bull Run: Can ProKidney Corp continue delivering strong returns2026 Key Highlights & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Winners Losers: Is ProKidney Corp impacted by rising rates2026 Market Sentiment & Fast Entry High Yield Stock Tips - baoquankhu1.vn
High stakes: ProKidney pushes toward commercialization as cash dwindles, opportunity awaits - The Business Journals
Is ProKidney (PROK) Stock suitable for dividend investors | Price at $1.88, Up 1.35%Expert Momentum Signals - Xã Châu Thành
Analysis Recap: Will ProKidney Corp benefit from government policyQuarterly Portfolio Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Can ProKidney (PROK) Stock Reach New Highs | Price at $1.81, Down 4.74%Social Buy Zones - Cổng thông tin điện tử tỉnh Lào Cai
April 2026 Penny Stock Highlights - Sahm
Prokidney Corp (PROK) 財務データ
収益
当期純利益
現金流量
EPS
0.67%
2.04%
大文字化:
|
ボリューム (24 時間):